San Francisco-based FibroGen Gets SFDA Nod Through Green Channel Procedure
This article was originally published in PharmAsia News
Executive Summary
HONG KONG - San Francisco-based FibroGen announced that Chinese regulators approved the start of clinical trials of novel therapy FG-4592 for anemia associated with chronic kidney disease. The approval was expedited through China's two-year-old special approval procedure, or "green channel.